Latest News & Updates
Breaking News
2 hours ago
Mrudula Kulkarni
Pharma Now Editorial Team
Other trending news you may like to read
Wockhardt Receives U.S. FDA Approval for ZAYNICH™ (cefepime and zidebactam), a Novel Intravenous Antibiotic for the Treatment of Adult Patients with Complicated Urinary Tract Infection Including Pyelonephritis
Wockhardt secures FDA approval for ZAYNICH (cefepime and zidebactam), a novel IV antibiotic for complicated UTIs, achieving 89% composite cure rate versus 68.4% for meropenem in Phase 3.
Mrudula Kulkarni
Idorsia Achieves Sustained Albuminuria Reductions with Aprocitentan in Phase 3 PRECISION Renal Analysis
Idorsia's Phase 3 PRECISION data show aprocitentan cuts albuminuria significantly through Week 36, strengthening the renal evidence base for potential label expansion.
Pharma Now Editorial Team
Roche Advances Enicepatide and Petrelintide Into Phase III While Initiating Combination Trial at ADA 2026
Roche advances enicepatide and petrelintide to Phase III and launches a combination trial, signalling significant CMC and manufacturing scale-up ahead.
Pharma Now Editorial Team
Idorsia Achieves High-Dose Immunogenicity Milestone in Phase 1 C. difficile Synthetic Glycan Vaccine Program
Idorsia's Phase 1 high-dose cohort confirms dose-dependent IgG immunogenicity for its synthetic glycan C. difficile vaccine, with partnership and scale-up next.
Pharma Now Editorial Team
